DALLAS - eTradeWire -- Lonestar Clinical Research is now enrolling participants for a clinical study in Dallas evaluating a treatment for Chronic Hepatitis C.

Chronic Hepatitis C is a major health concern in the Dallas area. 80% of the Hep C population in the Dallas / Fort Worth area is affected by the chronic, long-lasting infection. Chronic HCV infection remains the leading cause of chronic liver disease, hepatocellular carcinoma, and liver transplant.

"If you're living with Chronic Hepatitis C, your experience matters," said Dr. Ebuh, Principal Investigator at Lonestar Clinical Research. "This study offers an opportunity to access potential new treatment options at no cost and with no insurance required—while playing a vital role in advancing research that could benefit countless others affected by HCV in our community. At Lonestar, we're proud to bring innovative care and hope to the Dallas Fort Worth area."

More on eTradeWire News

• New Industry Article Explores Why Manufacturers Are Struggling to Find Skilled CNC Machinists
• Custom Patches Los Angeles Expands DTLA Factory to Solve Local Apparel Supply Chain Delays
• OWNER/CEO: Edward Rawlinson of Southside Recordz ~ (THE CONGLOMERATE) files "Civil Lawsuit"
• 2025 - 2026 IRS 1040 Tax Forms and Schedules Explained for Taxpayers Preparing Their Returns
• Little 6 Industries Launches Zero-Risk Merch Stores for Nonprofits and Schools

Why This Study Matters:
Chronic Hepatitis C impacts thousands across Dallas.
A new treatment is being evaluated for effectiveness and safety.
No cost. No insurance needed. Compensation available.

To learn more about the study or find out if you qualify, visit https://elixiastudies.com/chronic-hepatitis-c/
or call Lonestar Clinical Research at 214-227-7722

About Lonestar Clinical Research
We strive to provide every volunteer with the best level of care. Our friendly, experienced, and knowledgeable staff members make sure that each patient is informed, comfortable, and satisfied with their participation in clinical research.